Enterome (@enteromesa) 's Twitter Profile
Enterome

@enteromesa

Enterome is a clinical-stage biopharmaceutical company developing breakthrough immunomodulatory drugs for the treatment of cancer and inflammatory diseases.

ID: 4717731515

linkhttp://www.enterome.com calendar_today05-01-2016 19:46:29

488 Tweet

1,1K Followers

344 Following

Enterome (@enteromesa) 's Twitter Profile Photo

Many thanks to Labiotech.eu for featuring Enterome's CEO, Pierre Belichard on #BeyondBiotech. Pierre discusses the potential of our #OncoMimics pipeline produced using our Mimicry drug discovery platform & targeting difficult-to-treat cancers (18.13 mins) lnkd.in/dF_js_zs

Many thanks to <a href="/Labiotech_eu/">Labiotech.eu</a> for featuring Enterome's CEO, Pierre Belichard on #BeyondBiotech. Pierre discusses the potential of our #OncoMimics pipeline produced using our Mimicry drug discovery platform &amp; targeting difficult-to-treat cancers (18.13 mins) lnkd.in/dF_js_zs
Enterome (@enteromesa) 's Twitter Profile Photo

Next week our CBO, Anne Dagallier, will attend the Glioblastoma Drug Development Summit to discuss the progress of our Phase 2 ROSALIE #clinicalstudy evaluating lead #immunotherapy, EO2401, in patients with first progression/recurrence of #glioblastoma #GBMSummit2023 #gbmresearch

Next week our CBO, Anne Dagallier, will attend the Glioblastoma Drug Development Summit to discuss the progress of our Phase 2 ROSALIE #clinicalstudy evaluating lead #immunotherapy, EO2401, in patients with first progression/recurrence of #glioblastoma
#GBMSummit2023 #gbmresearch
Enterome (@enteromesa) 's Twitter Profile Photo

Enterome's team will attend #BIOEuropeSpring to meet potential partners and discuss the promising progress of our #clinical stage #OncoMimicsā„¢ peptide-based #immunotherapies. To arrange a meeting with the Enterome team, BIO-Europe’s partnering platform is now open.

Enterome's team will attend #BIOEuropeSpring to meet potential partners and discuss the promising progress of our #clinical stage #OncoMimicsā„¢ peptide-based #immunotherapies.
To arrange a meeting with the Enterome team, BIO-Europe’s partnering platform is now open.
Enterome (@enteromesa) 's Twitter Profile Photo

Our management team will attend BioTrinity 2023 in London. We look forward to discussing our first-in-class immunomodulatory drugs, including our #OncoMimicsā„¢ immunotherapies as potential breakthrough drugs for the treatment of solid and liquid tumors. #BioTrinity #biotech

Our management team will attend BioTrinity 2023 in London. 
We look forward to discussing our first-in-class immunomodulatory drugs, including our #OncoMimicsā„¢ immunotherapies as potential breakthrough drugs for the treatment of solid and liquid tumors. #BioTrinity #biotech
Enterome (@enteromesa) 's Twitter Profile Photo

We look forward to presenting new data from our Phase 2 #clinicaltrial (ROSALIE), evaluating our lead #OncoMimics #immunotherapy candidate EO2401 in patients with first progression/recurrence of #glioblastoma, at the ASCO Annual Meeting this year. lnkd.in/euzwwHBa

We look forward to presenting new data from our Phase 2 #clinicaltrial (ROSALIE), evaluating our lead #OncoMimics #immunotherapy candidate EO2401 in patients with first progression/recurrence of #glioblastoma, at the <a href="/ASCO/">ASCO</a> Annual Meeting this year. lnkd.in/euzwwHBa
Emmanuel Macron (@emmanuelmacron) 's Twitter Profile Photo

Ils innovent et portent des projets d’avenir, prometteurs et responsables. Pour le pays, leur rĆ“le demain sera clĆ©. Voici les 125 laurĆ©ats French Tech 2030. Nous allons les soutenir avec force.

Seventure Partners (@seventurep) 's Twitter Profile Photo

[Health for Life Capitalā„¢ portfolio] šŸ‘ Congrats! Enterome & Standing Ovation selected, over 840 applicants, as candidates for the investment plan ā€œFrance 2030ā€ led by the French General Secretary for Investment. #Microbiome #foodscience Isabelle de Cremoux

[Health for Life Capitalā„¢ portfolio] šŸ‘ Congrats!  <a href="/EnteromeSA/">Enterome</a> &amp; <a href="/S_O_Cheese/">Standing Ovation</a> selected, over 840 applicants, as candidates for the investment plan ā€œFrance 2030ā€ led by the French General Secretary for Investment.
#Microbiome #foodscience <a href="/IdeCremoux/">Isabelle de Cremoux</a>
Enterome (@enteromesa) 's Twitter Profile Photo

We're pleased to announce first patient dosed in Ph2 trial (CLAUDE) evaluating EO240 in #colorectalcancer with ctDNA-defined Minimal Residual Disease. EO2040 is Enterome’s fourth OncoMimics peptide-based #immunotherapy to enter #clinical development: lnkd.in/eSK2SRAC

We're pleased to announce first patient dosed in Ph2 trial (CLAUDE) evaluating EO240 in #colorectalcancer with ctDNA-defined Minimal Residual Disease.

EO2040 is Enterome’s fourth OncoMimics peptide-based #immunotherapy to enter #clinical development: lnkd.in/eSK2SRAC
A.n.n. (@fireflyann) 's Twitter Profile Photo

"The CLAUDE study (EOCRC1-22; NCT05350501) is the 1st trial to use liquid biopsy monitoring to measure ctDNA clearance as an indicator of OncoMimicsā„¢ immunotherapy efficacy." trial info crcmrd.com/?avada_portfol… video with PI Arvind Dasari, MD, MS crcmrd.com/?p=2590

MD Anderson Cancer Center (@mdandersonnews) 's Twitter Profile Photo

With a liquid biopsy, we can learn what’s going on inside a patient’s body by examining circulating tumor DNA (ctDNA). Explore how this technology works, its current limitations and future prospects, from our @AnthonyLucci1: fal.cn/3ArJS #LiquidBiopsy #EndCancer

Enterome (@enteromesa) 's Twitter Profile Photo

Enterome’s OncoMimicsā„¢ Immunotherapy EO2401 Significantly Improves Survival Rate in Recurrent Glioblastoma globenewswire.com/en/news-releas…

The Leukemia & Lymphoma Society (@llsusa) 's Twitter Profile Photo

What's the deal with clinical trials? šŸ¤” Valerie's insights as a #lymphoma survivor may interest you šŸ‘‰ bit.ly/3QOeeEq #ClinicalTrialsDay

Enterome (@enteromesa) 's Twitter Profile Photo

We're attending the the 2024 Jefferies Global Healthcare Conference which is taking place June 4-6 in NYC. Our CEO Pierre Belichard and CFO Christelle Dumoussaud will be available for 1:1 meetings. #JefferiesHealthcare

We're attending the the 2024 <a href="/Jefferies/">Jefferies</a>  Global Healthcare Conference which is taking place June 4-6 in NYC.  Our CEO Pierre Belichard and CFO Christelle Dumoussaud will be available for 1:1 meetings. #JefferiesHealthcare
The Leukemia & Lymphoma Society (@llsusa) 's Twitter Profile Photo

Excited to be at ASCO's annual meeting #ASCO24! Stay tuned to our channels as our LLS Therapy Acceleration Program (TAP) partners present new data on #BloodCancer science and innovation. Learn more about TAP šŸ‘‰ bit.ly/3Kns3pJ

Excited to be at <a href="/ASCO/">ASCO</a>'s annual meeting #ASCO24! Stay tuned to our channels as our LLS Therapy Acceleration Program (TAP) partners present new data on #BloodCancer science and innovation. Learn more about TAP šŸ‘‰ bit.ly/3Kns3pJ
The Leukemia & Lymphoma Society (@llsusa) 's Twitter Profile Photo

More exciting news is expected tomorrow at #ASCO24 from LLS TAP partners Enterome and Caribou Biosciences. ASCO šŸ”Ž Learn more about Caribou’s next-generation off-the-shelf cell therapy and Enterome’s therapeutic vaccine and how TAP is supporting their work šŸ‘‰ bit.ly/3yA1PO4

The Leukemia & Lymphoma Society (@llsusa) 's Twitter Profile Photo

.Enterome data was presented at #ASCO24 It highlighted complete response rates in non-Hodgkin lymphoma patients treated with their therapeutic vaccine combined with standard therapies. ASCOšŸ”ŽLearn more about the drug and LLS TAP’s role in it: šŸ‘‰msg.lls.org/3X96Ur6

The Leukemia & Lymphoma Society (@llsusa) 's Twitter Profile Photo

It’s our first-ever Dare to Dream Day! Show your support by 1) retweeting or creating a tweet with our new GIF šŸ‘‡ and 2) donating today! Because kids deserve better. With your support, dreams can come true. Donate now, and your gift will be TRIPLED šŸ‘‰ bit.ly/4c9SkDI

Enterome (@enteromesa) 's Twitter Profile Photo

Watch this insightful interview of Dr. Stephen Ansell from the Mayo Clinic on VJHemOnc to learn more about our novel immune therapy, EO2463, currently being evaluated in the phase 2 SIDNEY trial: youtu.be/oIZIOCDZb7w?si…